- Ongoing, recruitingTherapeutic confirmatory (Phase III)
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
This study looks at a new treatment called MaaT013 for gut-related GVHD. It's for people whose GVHD hasn't improved with standard medicine (ruxolitinib). Doctors want to see how well MaaT013 works in these patients.
For: Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.Germany · Belgium · Italy - Available
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
This early access program is for people with a serious gut condition called acute Graft-versus-Host Disease (aGvHD) that hasn’t responded to standard medicine (steroids). It's using an unapproved treatment called MaaT013 to see if it can help patients who have run out of other options.
For: Acute Graft Versus Host Disease in Intestine · Steroid Refractory GVHDAustria · Belgium · Canada